Malignancy of Hepatobiliary System or Pancreas with CC DRG Reimbursement

Clinical Trials

Neoadjuvant and perioperative therapy trials assessing systemic chemotherapy and/or radiotherapy strategies for borderline-resectable and locally advanced hepatobiliary and pancreatic malignancies. These studies enroll patients admitted for initial staging or preoperative treatment to evaluate tumor downstaging, resectability rates, pathologic response, and short-term perioperative morbidity. Results inform surgical candidacy, length of stay, ICU needs, and downstream costs relevant to inpatient reimbursement and DRG assignment.
Comparative effectiveness studies of endoscopic, percutaneous, and surgical biliary drainage and decompression in patients admitted with obstructive jaundice or cholangitis due to hepatobiliary or pancreatic cancer. Trials and pragmatic studies compare clinical outcomes (infection resolution, need for reintervention, procedure-related complications), timing of definitive oncologic therapy, and resource utilization across modalities and patient risk profiles. Findings are directly applicable to inpatient care pathways, influencing procedure selection, complication rates coded as CCs, and payer considerations for cost-effective management.
Post-discharge outcomes and palliative care integration cohort studies focused on readmissions, symptom control, and survival among patients with advanced hepatobiliary or pancreatic cancer who had inpatient stays for complications or initial therapy. These observational and interventional studies examine transitions of care, hospice/palliative involvement, and predictors of early readmission or high-cost utilization, helping hospitals and payers design discharge planning, case management, and value-based payment strategies to reduce avoidable inpatient utilization.

Other Hepatobiliary or Pancreas O.R. Procedures with MCC: Inpatient Reimbursement Overview

441-DISORDERS-OF-LIVER-EXCEPT-MALIGNANCY-CIRRHOSIS-OR-ALCOHOLIC-HEPATITIS-WITH-MCC

Disorders of Liver Except Malignancy, Cirrhosis or Alcoholic Hepatitis with MCC: Inpatient Reimbursement Overview

424-OTHER-HEPATOBILIARY-OR-PANCREAS-O-R-PROCEDURES-WITH-CC

Other Hepatobiliary or Pancreas O.R. Procedures with CC: Inpatient Reimbursement Overview

416-CHOLECYSTECTOMY-EXCEPT-BY-LAPAROSCOPE-WITHOUT-C-D-E-WITHOUT-CC-MCC

Cholecystectomy Except by Laparoscope without C.D.E. without CC/MCC: Inpatient Reimbursement Overview

411-CHOLECYSTECTOMY-WITH-C-D-E-WITH-MCC

Cholecystectomy with C.D.E. with MCC: Inpatient Reimbursement Overview

409-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITH-CC

Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E. with CC: Inpatient Reimbursement Overview

432-CIRRHOSIS-AND-ALCOHOLIC-HEPATITIS-WITH-MCC

Cirrhosis and Alcoholic Hepatitis with MCC: Inpatient Reimbursement Overview

408-BILIARY-TRACT-PROCEDURES-EXCEPT-ONLY-CHOLECYSTECTOMY-WITH-OR-WITHOUT-C-D-E-WITH-MCC

Biliary Tract Procedures Except Only Cholecystectomy with or without C.D.E. with MCC: Inpatient Reimbursement Overview

419-LAPAROSCOPIC-CHOLECYSTECTOMY-WITHOUT-C-D-E-WITHOUT-CC-MCC

Laparoscopic Cholecystectomy without C.D.E. without CC/MCC: Inpatient Reimbursement Overview

442-DISORDERS-OF-LIVER-EXCEPT-MALIGNANCY-CIRRHOSIS-OR-ALCOHOLIC-HEPATITIS-WITH-CC

Disorders of Liver Except Malignancy, Cirrhosis or Alcoholic Hepatitis with CC: Inpatient Reimbursement Overview

Showing 1–10 of 35

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Malignancy of Hepatobiliary System or Pancreas with CC: Inpatient Reimbursement Overview

DRG 436 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes